Literature DB >> 7854536

Treatment of myasthenia gravis by immunoadsorption of plasma.

D Grob1, D Simpson, H Mitsumoto, B Hoch, F Mokhtarian, A Bender, M Greenberg, A Koo, S Nakayama.   

Abstract

We treated 16 patients with moderately severe to severe generalized myasthenia gravis (MG) by immunoadsorption (perfusion through a resin that adsorbs proteins) of 2,500 ml plasma on each of four alternate days. Fourteen patients who completed treatment all had significant improvement in strength (6 excellent, 6 good, and 2 fair), which began a mean of 42 hours after the first immunoadsorption, reached a maximum 4 days after the fourth immunoadsorption (mean, 250% of baseline strength), and returned to baseline over a mean of 2 months. Thirty-seven grams of plasma proteins were removed during each immunoadsorption, which required no replacement, compared with 175 grams during plasma exchange, which requires replacement with albumin. Serum or plasma concentration of all proteins fell, more so for most of the larger proteins than for the smaller ones: acetylcholine receptor antibody (AChR Ab) fell to a mean of 23% of original level, fibrinogen to 26%, C4 to 29%, IgM to 33%, IgG to 35%, CH50 to 41%, C3 to 42%, IgA to 54%, and albumin to 76%. All proteins, including AChR Ab, returned to their original levels within 1 to 3 weeks after the last immunoadsorption, while improvement in strength lasted a mean of 6 weeks longer. One seronegative patient had excellent improvement lasting more than a month. Activated complement C5a and white blood cell count rose during each immunoadsorption, while activated complement C3a fell, and each returned to its original level within hours. Eight patients had transient symptomatic hypotension attributable to withdrawal of blood more rapidly than it was returned; this hypotension was prevented or ameliorated by intravenous saline.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7854536     DOI: 10.1212/wnl.45.2.338

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  10 in total

1.  Anaphylactoid reaction to immunoadsorptive membrane in a patient with myasthenia gravis.

Authors:  Yoshihiko Kanno; Shigeaki Suzuki; Tadashi Yoshida; Yugaku Date; Norihiro Suzuki; Matsuhiko Hayashi
Journal:  CEN Case Rep       Date:  2011-12-28

2.  [Immunoadsorption for steroid-unresponsive multiple sclerosis-relapses: clinical data of 14 patients].

Authors:  E Mauch; J Zwanzger; R Hettich; C Fassbender; R Klingel; F Heigl
Journal:  Nervenarzt       Date:  2011-12       Impact factor: 1.214

3.  In vivo adsorption of autoantibodies in myasthenia gravis using Nanodisc-incorporated acetylcholine receptor.

Authors:  Jian Rong Sheng; Steve Grimme; Palash Bhattacharya; Michael H B Stowell; Michael Artinger; Bellur S Prabahakar; Matthew N Meriggioli
Journal:  Exp Neurol       Date:  2010-07-15       Impact factor: 5.330

4.  [Therapeutic apheresis for autoimmune encephalitis: a nationwide data collection].

Authors:  S Ehrlich; C M Fassbender; C Blaes; C Finke; A Günther; L Harms; F Hoffmann; K Jahner; R Klingel; A Kraft; T Lempert; M Tesch; J Thomsen; H Topka; J Jochim; C Veauthier; W Köhler
Journal:  Nervenarzt       Date:  2013-04       Impact factor: 1.214

5.  Selective immune adsorption treatment of severe Guillain Barré syndrome in the intensive care unit.

Authors:  N Galldiks; C Dohmen; M Neveling; G R Fink; W F Haupt
Journal:  Neurocrit Care       Date:  2009-12       Impact factor: 3.210

Review 6.  Advances in autoimmune myasthenia gravis management.

Authors:  Shuhui Wang; Iva Breskovska; Shreya Gandhy; Anna Rostedt Punga; Jeffery T Guptill; Henry J Kaminski
Journal:  Expert Rev Neurother       Date:  2018-07-04       Impact factor: 4.618

7.  [Selective immunoadsorption in neurologic complications of systemic lupus erythematosus].

Authors:  S Harscher; S Rummler; P Oelzner; H-J Mentzel; M Brodhun; O W Witte; C Terborg; S Isenmann
Journal:  Nervenarzt       Date:  2007-04       Impact factor: 1.214

8.  The blood compatibilities of blood purification membranes and other materials developed in Japan.

Authors:  Takaya Abe; Karen Kato; Tomoaki Fujioka; Tadao Akizawa
Journal:  Int J Biomater       Date:  2011-09-28

9.  Therapeutic apheresis within immune-mediated neurological disorders: dosing and its effectiveness.

Authors:  Matthias Klingele; Carina Allmendinger; Solmaz Thieme; Lea Baerens; Danilo Fliser; Bürmann Jan
Journal:  Sci Rep       Date:  2020-05-13       Impact factor: 4.379

10.  Immunoadsorption therapy in autoimmune encephalitides.

Authors:  Müjgan Dogan Onugoren; Kristin S Golombeck; Corinna Bien; Mariam Abu-Tair; Marcus Brand; Michael Bulla-Hellwig; Hubertus Lohmann; Dieter Münstermann; Hermann Pavenstädt; Gerold Thölking; Rainer Valentin; Heinz Wiendl; Nico Melzer; Christian G Bien
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2016-02-26
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.